270 related articles for article (PubMed ID: 15055988)
1. 2-aminothiazole-derived opioids. Bioisosteric replacement of phenols.
Zhang A; Xiong W; Hilbert JE; DeVita EK; Bidlack JM; Neumeyer JL
J Med Chem; 2004 Apr; 47(8):1886-8. PubMed ID: 15055988
[TBL] [Abstract][Full Text] [Related]
2. Aminothiazolomorphinans with mixed κ and μ opioid activity.
Zhang T; Yan Z; Sromek A; Knapp BI; Scrimale T; Bidlack JM; Neumeyer JL
J Med Chem; 2011 Mar; 54(6):1903-13. PubMed ID: 21351746
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors.
Neumeyer JL; Zhang A; Xiong W; Gu XH; Hilbert JE; Knapp BI; Negus SS; Mello NK; Bidlack JM
J Med Chem; 2003 Nov; 46(24):5162-70. PubMed ID: 14613319
[TBL] [Abstract][Full Text] [Related]
4. Effects of substitution on the pyrrole N atom in derivatives of tetrahydronaltrindole, tetrahydrooxymorphindole, and a related 4,5-epoxyphenylpyrrolomorphinan.
Srivastava SK; Shefali S; Miller CN; Aceto MD; Traynor JR; Lewis JW; Husbands SM
J Med Chem; 2004 Dec; 47(26):6645-8. PubMed ID: 15588100
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties.
Mathews JL; Peng X; Xiong W; Zhang A; Negus SS; Neumeyer JL; Bidlack JM
J Pharmacol Exp Ther; 2005 Nov; 315(2):821-7. PubMed ID: 16076937
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and SAR study of opioid receptor ligands: mono- and bis-indolomorphinans.
Li F; Yin C; Chen J; Liu J; Xie X; Zhang A
Chem Biol Drug Des; 2009 Oct; 74(4):335-42. PubMed ID: 19691470
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors.
Peng X; Knapp BI; Bidlack JM; Neumeyer JL
J Med Chem; 2006 Jan; 49(1):256-62. PubMed ID: 16392810
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of 14-alkoxymorphinans. 21. Novel 4-alkoxy and 14-phenylpropoxy derivatives of the mu opioid receptor antagonist cyprodime.
Spetea M; Schüllner F; Moisa RC; Berzetei-Gurske IP; Schraml B; Dörfler C; Aceto MD; Harris LS; Coop A; Schmidhammer H
J Med Chem; 2004 Jun; 47(12):3242-7. PubMed ID: 15163203
[TBL] [Abstract][Full Text] [Related]
9. 10-Ketomorphinan and 3-substituted-3-desoxymorphinan analogues as mixed kappa and micro opioid ligands: synthesis and biological evaluation of their binding affinity at opioid receptors.
Zhang A; Xiong W; Bidlack JM; Hilbert JE; Knapp BI; Wentland MP; Neumeyer JL
J Med Chem; 2004 Jan; 47(1):165-74. PubMed ID: 14695830
[TBL] [Abstract][Full Text] [Related]
10. Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
Ananthan S; Khare NK; Saini SK; Seitz LE; Bartlett JL; Davis P; Dersch CM; Porreca F; Rothman RB; Bilsky EJ
J Med Chem; 2004 Mar; 47(6):1400-12. PubMed ID: 14998329
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of 14-alkoxymorphinans. 18. N-substituted 14-phenylpropyloxymorphinan-6-ones with unanticipated agonist properties: extending the scope of common structure-activity relationships.
Greiner E; Spetea M; Krassnig R; Schüllner F; Aceto M; Harris LS; Traynor JR; Woods JH; Coop A; Schmidhammer H
J Med Chem; 2003 Apr; 46(9):1758-63. PubMed ID: 12699394
[TBL] [Abstract][Full Text] [Related]
12. Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors.
Thompson CM; Wojno H; Greiner E; May EL; Rice KC; Selley DE
J Pharmacol Exp Ther; 2004 Feb; 308(2):547-54. PubMed ID: 14600248
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist.
Neilan CL; Husbands SM; Breeden S; Ko MC; Aceto MD; Lewis JW; Woods JH; Traynor JR
Eur J Pharmacol; 2004 Sep; 499(1-2):107-16. PubMed ID: 15363957
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the in vitro efficacy of mu, delta, kappa and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes.
Lester PA; Traynor JR
Brain Res; 2006 Feb; 1073-1074():290-6. PubMed ID: 16443205
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and opioid receptor activity of indolopropellanes.
Li F; Gaob L; Yin C; Chen J; Liu J; Xie X; Zhang A
Bioorg Med Chem Lett; 2009 Aug; 19(16):4603-6. PubMed ID: 19595591
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and pharmacological evaluation of 6,7-indolo/thiazolo-morphinans--further SAR of levorphanol.
Zhang A; Li F; Ding C; Yao Q; Knapp BI; Bidlack JM; Neumeyer JL
J Med Chem; 2007 May; 50(11):2747-51. PubMed ID: 17488103
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.
Peng X; Knapp BI; Bidlack JM; Neumeyer JL
J Med Chem; 2007 May; 50(9):2254-8. PubMed ID: 17407276
[TBL] [Abstract][Full Text] [Related]
18. An investigation of the N-demethylation of 3-deoxymorphine and the affinity of the alkylation products to mu, delta, and kappa receptors.
Csutoras C; Zhang A; Bidlack JM; Neumeyer JL
Bioorg Med Chem; 2004 May; 12(10):2687-90. PubMed ID: 15110850
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and binding affinity of novel mono- and bivalent morphinan ligands for κ, μ, and δ opioid receptors.
Zhang B; Zhang T; Sromek AW; Scrimale T; Bidlack JM; Neumeyer JL
Bioorg Med Chem; 2011 May; 19(9):2808-16. PubMed ID: 21482470
[TBL] [Abstract][Full Text] [Related]
20. [Old and new mu-opioids. Mu-selective opioids with a morphinan structure].
Buschmann H; Sundermann B; Maul C
Pharm Unserer Zeit; 2002; 31(1):44-50. PubMed ID: 11852656
[No Abstract] [Full Text] [Related]
[Next] [New Search]
